Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4999941 | 0.84 | KMT2A (0.94) | LMNAKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL13563662 | 0.84 | ALDH1A1 (0.64) | LMNAKMT2AALDH1A1MEN1CYP1A2 | |
| SCHEMBL11847732 | 0.79 | KDM4E (0.76) | LMNAKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL3825736 | 0.78 | ALDH1A1 (0.61) | KMT2AALDH1A1MEN1KDM4ECYP1A2 | |
| SCHEMBL17482339 | 0.78 | BCHE (0.69) | LMNAKMT2AMEN1KDM4EHTT | |
| SCHEMBL15303789 | 0.76 | KDM4E (0.83) | LMNAKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL11843383 | 0.76 | MEN1 (0.52) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL13563659 | 0.75 | ALDH1A1 (0.57) | KMT2AALDH1A1MEN1KDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL10334554 | 0.75 | KDM4E (0.81) | LMNAKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL10520895 | 0.74 | POLB (0.83) | LMNAKMT2AALDH1A1MEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1773880-A4 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| EP-1773880-A2 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2005121175-A9 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | CHIRON CORP (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2005121175-A2 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | CD4, CD74, HAVCR2 | LMNA 4015/4885KMT2A 4731/4885ALDH1A1 4880/4885 |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | CD4, CD74, HAVCR2 | LMNA 4015/4885KMT2A 4731/4885ALDH1A1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.